Ridge Biotechnologies

Ridge Biotechnologies (Ridge Bio) is a Palo Alto-based biotechnology company pioneering machine learning-driven enzyme and conditionally-activated drug design to enable next-generation precision therapeutics. The company's platform utilizes proprietary machine learning models built on massive, high-throughput cell-free datasets to design precision enzymes and targeted delivery systems at unprecedented speed and scale. Ridge Bio's initial product lines include NativeLink™ enzymes, which enable precise, site-specific bioconjugation without altering protein sequences, glycans, or disulfide bonds, and ProTrigger™ protease-cleavable linkers, which allow for selective drug release in target tissues like the tumor microenvironment. Additionally, the company is developing a new class of precision enzyme-based therapeutics known as Catalytic Medicines™. Backed by leading investors including Sutter Hill Ventures and Dimension Capital, Ridge Bio collaborates with biopharma partners to optimize antibody-drug conjugates (ADCs), peptide conjugates, and other advanced modalities.